



Innovation in Antibody-Drug Conjugates (ADCs)

Guest Editors:

Prof. Dr. Naoto T. Ueno

Department of Breast Medical
Oncology, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Prof. Dr. Jennifer Maynard

1. Department of Biochemistry,
The University of Texas at Austin,
Austin, TX 78712, USA
2. McKetta Department of
Chemical Engineering, The
University of Texas at Austin,
Austin, TX 78712, USA

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

The recent approval by many regulatory boards of various Antibody-drug conjugates (ADC) had a dramatic improvement in the outcome of cancer patients. Since the first approval of ADC more than 20 years ago, there has been a major effort to improve its efficacy of ADC. This overall efficacy ADC is defined by antibody, linker, and payload. Further, these factors will impact the overall toxicities. This Special Issue of ADC allows us to present the latest research related to ADC and collectively show the future of ADC research direction. We are pleased to invite you to address the innovative approach to treating cancer by ADC, novel modification, and the translational and clinical impact of ADC in cancer management.

Prof. Dr. Naoto T. Ueno

Prof. Dr. Jennifer Maynard

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)